Wedbush Securities Inc. Has $555,000 Position in Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Wedbush Securities Inc. boosted its holdings in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 34.5% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 6,979 shares of the biopharmaceutical company’s stock after acquiring an additional 1,790 shares during the quarter. Wedbush Securities Inc.’s holdings in Intercept Pharmaceuticals were worth $555,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Financial Gravity Wealth Inc. acquired a new stake in Intercept Pharmaceuticals in the 1st quarter valued at $33,000. AdvisorNet Financial Inc acquired a new stake in Intercept Pharmaceuticals in the 2nd quarter valued at $56,000. Botty Investors LLC acquired a new stake in Intercept Pharmaceuticals in the 1st quarter valued at $84,000. Shell Asset Management Co. acquired a new stake in Intercept Pharmaceuticals in the 1st quarter valued at $231,000. Finally, Hanseatic Management Services Inc. grew its position in Intercept Pharmaceuticals by 12.1% in the 1st quarter. Hanseatic Management Services Inc. now owns 2,077 shares of the biopharmaceutical company’s stock valued at $232,000 after purchasing an additional 224 shares during the period. 77.24% of the stock is owned by institutional investors and hedge funds.

ICPT traded down $0.60 during mid-day trading on Friday, reaching $64.04. 3,584 shares of the stock were exchanged, compared to its average volume of 653,133. The company has a debt-to-equity ratio of 3.11, a quick ratio of 3.72 and a current ratio of 6.54. The stock has a market capitalization of $2.16 billion, a PE ratio of -5.90 and a beta of 1.32. The company has a 50 day moving average price of $69.81 and a two-hundred day moving average price of $90.38. Intercept Pharmaceuticals Inc has a 1 year low of $58.21 and a 1 year high of $133.74.



Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($2.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($2.51) by $0.23. The firm had revenue of $66.30 million for the quarter, compared to the consensus estimate of $58.78 million. Intercept Pharmaceuticals had a negative net margin of 143.57% and a negative return on equity of 534.42%. The business’s revenue for the quarter was up 52.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.58) EPS. Sell-side analysts expect that Intercept Pharmaceuticals Inc will post -10 EPS for the current fiscal year.

Several analysts recently issued reports on the stock. Cowen reissued a “buy” rating and issued a $149.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, May 8th. B. Riley reissued a “buy” rating and issued a $169.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, May 8th. BidaskClub raised shares of Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 9th. Zacks Investment Research raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $73.00 price target for the company in a research report on Monday, July 15th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $86.00 price objective on shares of Intercept Pharmaceuticals in a report on Monday. Three analysts have rated the stock with a sell rating, six have given a hold rating and fifteen have issued a buy rating to the stock. Intercept Pharmaceuticals has an average rating of “Buy” and a consensus price target of $138.86.

In related news, insider Lisa Bright sold 595 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $78.66, for a total value of $46,802.70. Following the transaction, the insider now directly owns 20,452 shares of the company’s stock, valued at approximately $1,608,754.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 5.00% of the stock is currently owned by insiders.

Intercept Pharmaceuticals Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Story: What moving averages are used to define a golden cross?

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals Inc (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.